# Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

> **NCT03549338** · PHASE2 · TERMINATED · sponsor: **Symphogen A/S** · enrollment: 2 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- Colorectal Cancer Metastatic
- Carcinoma

## Interventions

- **DRUG:** Sym004
- **DRUG:** Futuximab
- **DRUG:** Modotuximab

## Key facts

- **NCT ID:** NCT03549338
- **Lead sponsor:** Symphogen A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-29
- **Primary completion:** 2019-03-01
- **Final completion:** 2019-03-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study was terminated due to administrative reasons
- **Last updated:** 2020-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03549338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03549338, "Sym004 Versus Futuximab or Modotuximab in Patients With mCRC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03549338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*